Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Supplement Article
You have accessRestricted Access

Novel Cardiovascular Risk Factors in End-Stage Renal Disease

Carmine Zoccali, Francesca Mallamaci and Giovanni Tripepi
JASN January 2004, 15 (1 suppl) S77-S80; DOI: https://doi.org/10.1097/01.ASN.0000093240.84097.FE
Carmine Zoccali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Mallamaci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Tripepi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

ABSTRACT. Traditional risk factors only in part explain the risk differential between the general population and the population of patients with chronic nephropathies. Uncontrolled hyperphosphatemia and high calcium phosphate product constitute risk factors for cardiovascular calcifications, cardiac ischemia, and adverse cardiovascular outcomes, yet inflammation may be an even more important trigger of vascular calcification than these metabolic derangements. Homocysteine predicts cardiovascular events in ESRD, but evidence that this sulfur amino acid is directly implicated in the high cardiovascular mortality of uremic patients is still lacking. It seems unlikely that Chlamydia pneumoniae is a major risk factor in dialysis patients because the association between anti-Chlamydia antibodies and incident cardiovascular events seems to depend largely on the confounding effect of some traditional risk factors. Oxidative stress and raised plasma concentration of asymmetric dimethylarginine (ADMA) are pervasive in ESRD, and high ADMA in these patients may be at least in part the expression of the high rate of generation of oxidants. ADMA per se seems responsible for a 52% increase in the risk of death and for a 34% increase in the risk of cardiovascular events in dialysis patients.

Cardiovascular risk in patients with ESRD has now gained center stage in clinical research. The interest on this issue is motivated by the striking risk differential for coronary heart disease between the dialysis population and the general population. The problem may be seen as the final, catastrophic consequence of a process that starts very early in renal diseases (1). Cardiovascular risk in renal insufficiency is perceived as an important public health problem, and preventing and curing cardiovascular complications in patients with renal dysfunction is considered a true priority (2). Prevention and treatment strategies demand precise knowledge of risk factors and of the possibility of modifying them with appropriate treatments.

This review focuses on the end-stage phase of chronic renal failure, i.e., the stage in which only secondary or tertiary prevention measures can be taken. The issue has been investigated intensively in the past 10 yr, and emerging evidence indicates that novel rather than traditional risk factors dominate the scene in this clinical condition. Here I only briefly touch on traditional risk factors and circumscribe the discussion to their relationship with inflammatory mechanisms. I then move the focus on vascular calcifications and alterations in calcium phosphate metabolism (i.e., on a risk factor peculiar to chronic renal failure) to end with emerging risk factors.

Atherosclerosis as an Inflammatory Disease: C Reactive Protein in Dialysis Patients

According to Ross’ theory (3), endothelial dysfunction is the initial event of atherosclerosis. Insults may be of various nature (e.g., metabolic, physical, infectious). As an expression of such dysfunction, the endothelium synthesizes and releases vasoactive and adhesion molecules, cytokines, and growth factors. Macrophages adhere to dysfunctional endothelium and then migrate into the arterial wall to become the key element in the formation and in the evolution of the atherosclerotic plaque.

In the general population, substantial evidence has been accrued that atherosclerosis underlies a systemic microinflammatory process and that serum C reactive protein (CRP) is a reliable risk marker of atherosclerotic complications. In patients with ESRD, serum CRP represents a strong predictor of death (4) and adverse cardiovascular events. As discussed in detail elsewhere (5), inflammation in ESRD is a multifactorial process, and it seems likely that this process, at least in part, mediates the effect of most traditional and nontraditional risk factors.

Inflammation, the Endothelium, and Hypertension Triggers

Hypertension is a complex phenotype because causative factors implicated in hypertension, such as angiotensin II, sympathetic activity, and chronic volume overload, besides triggering hypertension, exert inflammatory and growth-promoting effects on the cardiovascular system. Angiotensin II is a potent vasoconstrictor as well as a proinflammatory substance and a recognized growth promoter. Double transgenic rats that overexpress the angiotensinogen and renin gene display marked left ventricular hypertrophy. A similar process may be operative in ESRD disease because it has been shown that left ventricular mass in these patients is directly related to plasma renin activity (6). Likewise, the sympathetic system is not only a major regulator of cardiovascular function but also an important control mechanism of the immune response and of inflammation (7). The interference of the sympathetic system with inflammation in cardiovascular diseases is exemplified by the observations that in a syndrome characterized by high sympathetic tone such as dilated cardiomyopathy, the plasma concentration of the inflammatory cytokine TNF-α is markedly raised and that β-blockers cause a substantial decrease in plasma TNF-α (8). Furthermore, very recent findings suggest that in patients with high CRP and stable coronary heart diseases, β-blockers reduce exercise-inducible myocardial ischemia (9). Norepinephrine is also a recognized growth promoter for myocardial cells. In this regard, it is interesting to note that in patients with ESRD, independent of BP, circulating norepinephrine is directly related to the muscular component of the left ventricle (the mean ventricular wall) (10) (Figure 1) and that it is a strong and independent predictor of cardiovascular death (11).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Relationship between plasma norepinephrine (expressed in tertiles) and concentric left ventricular hypertrophy in ESRD patients.

Chronic volume overload is a major cardiovascular stressor. In the long term, the deleterious effects of volume overload depend to an important extent on the fact that the hemodynamic burden activates a series of adaptive processes that modify profoundly the very structure of the myocardium. An increased amount of fibroblasts and macrophages is commonly observed in the volume-overloaded, failing heart. Monocyte chemoattractant protein, an inflammatory protein, is overexpressed in cardiomyocytes of rats with volume-overload congestive heart failure (12). Overexpression of this protein does not represent a late event in this process because it is evident also in rats with compensated heart failure. Of note, stress-activated cytokines play a well-defined role in the functional and anatomical (left ventricular remodeling) adaptations to volume overload, and it is well demonstrated that TNF and IL-6 are overexpressed in the volume-overloaded, failing human myocardium (13). Fibrinogen is an acute-phase reactant of particular interest in relation to volume overload because evidence is emerging that this pro-coagulant protein is responsive to volume stimuli. Indeed, in hemodialysis patients who do not have systemic evidence of inflammation and display raised plasma volume, the synthesis rate and the plasma concentration of fibrinogen is increased (14). This increase has been interpreted as a physiologic response aimed at counteracting hemodilution and at restoring the plasma concentration of this protein (15). Because the plasma concentration of fibrinogen reflects two powerful cardiovascular-event triggers (inflammation and volume overload), it is expected that this factor is a strong predictor of adverse outcomes. In keeping with this hypothesis, in a recent analysis adjusting for other risk factors, a 200-mg/dl increase in plasma fibrinogen (the average difference in plasma fibrinogen between healthy subjects and dialysis patients) was associated with a 50% increase in cardiovascular risk (16).

Phosphate, Vascular Calcifications, and Inhibitors of Calcification

Uncontrolled hyperphosphatemia and high calcium phosphate product constitute risk factors for cardiovascular calcifications, cardiac ischemia, and adverse cardiovascular outcomes (17), yet alterations in phosphate and in calcium metabolism do not represent the sole cause of vascular calcifications in ESRD patients. Osteoclast-like cells are normally demonstrable in heart valves and in arterial vessels, and it is interesting to note that alkaline phosphatase activity in these cells is much enhanced when they are co-cultured with macrophages (18). This in vitro observation seems to be of importance because it provides a rational link between inflammation, derangements in calcium-phosphate metabolism, and vascular calcification. Osteoclast-like cells seem to be incorporated into bone-like lamellae in calcified lesions. Because this process is a true “ossification” of the vascular wall, it may involve an alteration in the balance between factors that promote calcification and those that inhibit the deposition of calcium salts. A relative lack of protective factors seems to be of relevance because vascular calcifications in ESRD have been linked to low levels of the calcification-inhibitor fetuin (19). Fetuin is an intriguing glycoprotein because it is a calcification inhibitor as well as an inverse acute-phase reactant (like serum albumin), i.e., it is markedly reduced during inflammatory processes. Of note, a low plasma concentration of this substance has been recently associated with a high rate of incident cardiovascular events in dialysis patients.

Hyperhomocysteinemia and Infections

Hyperhomocysteinemia and infections, particularly Chlamydia pneumoniae infections, have been implicated as potential triggers of atherosclerotic complications in patients with chronic renal diseases. Hyperhomocysteinemia was associated with high cardiovascular morbidity in two cohort studies in dialysis patients (20,21⇓), and ongoing intervention trials will establish whether reducing the plasma concentration of this substance may improve cardiovascular outcomes in ESRD. In contrast, the role of Chlamydia pneumoniae in the high cardiovascular mortality in these patients remains uncertain because the association between anti-Chlamydia antibodies and incident cardiovascular events seems to depend largely on the confounding effect of some traditional risk factors (22).

Oxidative Stress and Asymmetric Dimethyl-Arginine

In this and another review (5), we examined in some detail the hypothesis that in patients with ESRD, several traditional and emerging risk factors may damage the cardiovascular system by inflammatory mechanisms. However, the high cardiovascular risk of ESRD may depend not only on a high burden of emerging risk factors such as homocysteine or high sympathetic activity but also on a relative lack of vasculoprotective factors.

Under normal conditions, nitric oxide (NO) is continuously generated in the endothelium by the enzyme NO synthase (NOS), which transforms l- arginine into NO and citrulline (Figure 2). NO has a protective role for the cardiovascular system because it inhibits vascular muscle cell proliferation, platelet aggregability, and the adhesion of monocytes to the endothelium. NOS can be inhibited by endogenous methylarginines, and asymmetric dimethylarginine (ADMA) seems to be the most important of these endogenous NOS inhibitors. ADMA is in part excreted by the kidney, but this compound is mainly disposed by transformation into citrulline, a reaction driven by the enzyme diethyl-diamino-hydrolase. Diethyl-diamino-hydrolase is present within the endothelial cells and is very sensitive to oxidative stress (23) (Figure 2). Oxidative stress is pervasive in ESRD (24); therefore, high ADMA in this condition may be the expression of the high rate of generation of oxidants. ADMA per se seems responsible for a 52% higher risk of death and for a 34% higher risk of cardiovascular events in dialysis patients (25). Besides predicting incident cardiovascular events, high ADMA is strongly associated with well-established risk markers such as increased intima-media thickness in the carotid arteries (26) and concentric left ventricular hypertrophy (27).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Basic biochemical steps regulating nitric oxide synthesis.

ADMA is a potentially modifiable risk factor. Treatments aimed at reducing oxidative stress or high doses of the NO precursor l-arginine constitute interesting opportunities for intervention on this putative risk factor. Perhaps further information on the role of ADMA in cardiovascular complications in ESRD will be gained as spin-off of trials aimed at reducing hypercholesterolemia, inflammation, and oxidative stress in uremics on chronic dialysis treatment like the 4D study (28).

  • © 2004 American Society of Nephrology

References

  1. ↵
    Zoccali C: Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention. Nephrol Dial Transplant 17 [Suppl 11]: 50–54, 2002
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Levin A, Stevens L, McCullough PA: Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. Postgrad Med 111: 53–60, 2002
    OpenUrlCrossRef
  3. ↵
    Ross R: Atherosclerosis. An inflammatory disease. N Engl J Med 340: 115–126, 1999
    OpenUrlCrossRefPubMed
  4. ↵
    Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 62: 1791–1798, 2002
    OpenUrlCrossRefPubMed
  5. ↵
    Zoccali C: Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 21: 29–36, 2003
    OpenUrlCrossRefPubMed
  6. ↵
    Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 8: 1764–1770, 1997
    OpenUrlAbstract
  7. ↵
    Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve—An integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 52: 595–638, 2000
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37: 412–417, 2001
    OpenUrlCrossRefPubMed
  9. ↵
    Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA: C-Reactive protein and ischemia in users and nonusers of β-blockers and statins: Data from the Heart and Soul Study. Circulation 107: 245–250, 2003
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40: 41–46, 2002
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cataliotti A: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354–1359, 2002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, Winaver J: Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 102: 1315–1322, 2000
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Mann DL: Stress activated cytokines and the heart: From adaptation to maladaptation. Annu Rev Physiol 65: 81–101, 2003
    OpenUrlCrossRefPubMed
  14. ↵
    Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L, Zoccolo AM, Castellino P: Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol 12: 349–354, 2001
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L, Levin NW; The HEMO Group: Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int 63: 315–322, 2003
    OpenUrlCrossRefPubMed
  16. ↵
    Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M: Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254: 132–139, 2003
    OpenUrlCrossRefPubMed
  17. ↵
    Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14: 159–168, 2003
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL: Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 105: 650–655, 2002
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-Dechent W, Floege J: Novel insights into uremic vascular calcification: Role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood Purif 20: 473–476, 2002
    OpenUrlCrossRefPubMed
  20. ↵
    Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138–141, 1998
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61: 609–614, 2002
    OpenUrlCrossRefPubMed
  22. ↵
    Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Bonanno G, Seminara G, Fatuzzo G, Rapisarda F, Malatino LS: Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney Int 64: 579–584, 2003
    OpenUrlCrossRefPubMed
  23. ↵
    Cooke JP: Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20: 2032–2037, 2000
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524–1538, 2002
    OpenUrlCrossRefPubMed
  25. ↵
    Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113–2117, 2001
    OpenUrlCrossRefPubMed
  26. ↵
    Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490–496, 2002
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62: 339–345, 2002
    OpenUrlCrossRefPubMed
  28. ↵
    Wanner C, Krane V, Ruf G, März W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on haemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222–S226, 1999
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 15 (1 suppl)
Journal of the American Society of Nephrology
Vol. 15, Issue 1 suppl
1 Jan 2004
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Novel Cardiovascular Risk Factors in End-Stage Renal Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Novel Cardiovascular Risk Factors in End-Stage Renal Disease
Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi
JASN Jan 2004, 15 (1 suppl) S77-S80; DOI: 10.1097/01.ASN.0000093240.84097.FE

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Novel Cardiovascular Risk Factors in End-Stage Renal Disease
Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi
JASN Jan 2004, 15 (1 suppl) S77-S80; DOI: 10.1097/01.ASN.0000093240.84097.FE
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Atherosclerosis as an Inflammatory Disease: C Reactive Protein in Dialysis Patients
    • Inflammation, the Endothelium, and Hypertension Triggers
    • Phosphate, Vascular Calcifications, and Inhibitors of Calcification
    • Hyperhomocysteinemia and Infections
    • Oxidative Stress and Asymmetric Dimethyl-Arginine
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension
  • Increased Sodium-Lithium Countertransport Activity: A Cellular Dysfunction Common to Essential Hypertension and Diabetic Nephropathy
  • Hypertensive Renal Damage in Metabolic Syndrome Is Associated with Glucose Metabolism Disturbances
Show more Supplement Article

Cited By...

  • Nickel exposure and prevalent albuminuria and {beta}2-microglobulinuria: evidence from a population-based study
  • Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin
  • Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients
  • The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease
  • Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease
  • Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E-Deficient Mice
  • Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire